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Chronic lymphocytic leukemia (CLL) patients who relapse soon after first-line treatment with fludarabine-based chemoimmunotherapy often survive for only a couple of years.
1 Glucocorticoids can kill fludarabine-resistant CLL cells in vitro and high-dose glucocorticoids (HDGCs) have activity against such cells in vivo 2 perhaps by intercalating into their membranes and interfering with signaling and bioenergetic pathways. 3 Rituxan improves the efficacy of HDGCs, and the combination has been reported to induce complete response rates of up to 25%. 4, 5 Ofatumumab is a CD20 antibody with binding properties that may confer greater activity against tumors with low CD20 expression such as CLL. Single-agent ofatumumab is reported to have a 40 --50% response rate in fludarabine and alemtuzumab refractory disease but only 14% in patients with both bulky (45 cm) lymph nodes and tumor cells with 17p deletions.
1
Ofatumumab is available in Canada through a special access program for CLL patients who are refractory to fludarabine and alemtuzumab or ineligible for the latter on the basis of bulky disease. We report our experience with 13 such patients concomitantly treated with HDGCs.
HDGCs are conventionally given intravenously, which imposes a burden on cancer center resources and requires scheduling that may delay treatment. Beyond CLL, HDGCs are used to treat inflammatory diseases such as multiple sclerosis where clinical studies support the bio-equivalence of oral and intravenous glucocorticoids and gastric safety of high-dose oral steroids.
6
These results were adapted directly to CLL, and intravenous HDGCs were replaced with oral HDGCs for the last 7/13 patients.
A test dose (300 mg) of ofatumumab was given on week 1, followed by 7 weekly injections of 2 gm, and then 2 gm every 4 weeks for 4 further injections. HDGCs were given every 28 days until disease progression, or until an alternative therapy could be administered. Intravenous HDGCs consisted of 1 gm/m 2 Methylprednisolone daily for 5 days.
2,4,5 Oral HDGCs consisted of 1250 mg/m 2 prednisone daily for 5 days or 187.5 mg/m 2 dexamethasone daily for 4 days owing to its longer half-life. Prophylactic Septra, acyclovir and bisphosphonates were given to all patients. Lamivudine was given to patients at risk for hepatitis B reactivation. All patients had hypogammaglobulinemia, and immunoglobulin replacement was given to patients 1, 4, 7, 8, 9, 12 and 13.
Patient characteristics are described in Table 1 . All had bulky fludarabine-refractory disease to be eligible for ofatumumab; 12/13 were men, and 8 had 17p deletions. Treatments were well tolerated, the major side effects being fatigue and fluid retention from HDGCs that responded easily to diuretics. Infections were not a major problem, perhaps, because of the number of patients on concomitant immunoglobulin replacement.
No complete responses were observed in the cohort. However, 10/13 ¼ 78% of all patients, and 5/8 ¼ 62% of the patients with 17p deletions, had partial responses, defined as a decrease in peripheral lymphocytes by o50% for at least 2 months and an increase in hemoglobin or platelet counts of 50%.
7 Progression free survival could not be evaluated since an attempt was made to provide T-cell therapy to these high-risk patients in the form of allogeneic bone marrow transplantation (patient 8) or autologous T cells genetically modified to express an anti-CD19 chimeric antigen receptor (patients 1, 6, 9, 11).
8 Alternatively, lenalidomide (Revlimid; Celgene Corporation, Summit, NJ, USA) was obtained for others (patients 2, 4, 7, 13). Importantly, no differences in response rates were noted with oral HDGCs, and patients much preferred this regimen.
Whereas these results must be confirmed in phase II trials, our experience suggests that HDGCs coupled with ofatumab has a higher response rate in Fludarabine-refractory patients than single-agent ofatumumab 1 and may be used as bridge to transplant for some patients. Importantly, the oral route is an option for delivering HDGCs to CLL patients with a number of logistical advantages over daily intravenous administration. However, HDGCs with ofatumumab remains a palliative regimen and the mechanisms of glucocorticoid and antibody resistance must be better understood to improve therapeutic efficacy. Abbreviations: C, cyclophospamide; Cam, alemtuzumab; Ch, chlorambucil; F, fludarabine; H, adriamycin; LDT, lymphocyte doubling time; O, vincristine; P, prednisone; M, mitoxanthrone; R, rituxan; Rev, revlimid; Sp, splenectomy; V, VP16.
a Normal serum b2 M levels are less than 2.3 mg/L. b Normal LDH levels are less than 250 IU/ml.
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Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis Leukemia (2012 Leukemia ( ) 26, 1145 Leukemia ( --1147 doi:10.1038 /leu.2011 published online 11 November 2011 In its simplest description, apoptosis is a cell death process largely regulated by the Bcl-2 family that is composed of antiapoptotic proteins (Bcl-2, Bcl-xL, Mcl-1, A1...) as opposed to pro-apoptotic members (Bax, Bak, Bim...).
1 Overexpression of anti-apoptotic members is among the best-characterized cause of apoptosis resistance. The anti-apoptotic activity of some proteins of this family can now be manipulated pharmacologically, using 
